Covista
CVSA
127.30
-0.07
-0.06%
Covista
US · CVSA
#2249 by market cap
Listed 1970
127.30
-0.07
-0.06%
Live - 5344 symbols - heartbeat 19s ago
· 2026-10-08 08:19
Pre-market
126.97
-0.26%
After-hours
127.30
0.00%
- Market cap
- 4.31B
- P/E (TTM)i
- 18.08
- P/Bi
- 2.98
- EPSi
- 7.04
- Div yieldi
- 0.00%
- 52W posi
- 58%
Reader sentiment
Are you bullish or bearish on CVSA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.16, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.27% YoY
Margins
- Gross margin
- 57.34%
- Operating margin
- 19.94%
- Net margin
- 12.87%
Key ratios & quality
- Enterprise valuei
- 4.60B
- PEG ratioi
- 0.46
- Altman Z-Scorei
- 4.16
PEG uses trailing P/E against the 3-year net income growth rate (39.16%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.01B | 866.43M | 899.25M | 1.38B | 1.45B | 1.58B | 1.79B | 1.95B |
| Gross profit | 542.06M | 409.26M | 441.34M | 722.07M | 802.34M | 886.10M | 1.02B | 1.12B |
| Selling & admin expenses | 359.34M | 280.29M | 292.48M | 566.49M | 586.01M | 632.97M | 672.00M | 730.72M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 182.72M | 128.97M | 148.86M | 155.57M | 216.33M | 253.14M | 344.86M | 389.71M |
| Pretax profit | 139.75M | 204.99M | 75.77M | -51.49M | 112.04M | 163.94M | 298.51M | 345.12M |
| Tax | 32.88M | -14.94M | 12.32M | -15.54M | 10.28M | 26.22M | 65.84M | 77.74M |
| Net profit | 95.58M | -85.78M | 69.59M | 310.99M | 93.36M | 136.78M | 237.07M | 251.57M |
| Basic EPS | 2 | -2 | 1 | 6 | 2 | 3 | 6 | 7 |
| Diluted EPS | 1.60 | -1.59 | 1.36 | 6.43 | 2.05 | 3.39 | 6.18 | 7.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 466.06M | 457.11M | 462.29M | 503.39M | 487.03M | 501.38M |
| Gross profit | 266.19M | 258.18M | 261.52M | 297.96M | 276.31M | 284.63M |
| Selling & admin expenses | 175.17M | 180.86M | 175.73M | 182.79M | 184.11M | 188.09M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 91.02M | 77.31M | 85.79M | 115.17M | 92.21M | 96.54M |
| Pretax profit | 79.33M | 68.58M | 76.87M | 101.90M | 77.95M | 88.40M |
| Tax | 18.54M | 14.12M | 15.81M | 25.73M | 19.96M | 16.24M |
| Net profit | 60.83M | 54.21M | 61.83M | 76.38M | 41.64M | 71.72M |
| Basic EPS | 2 | 2 | 2 | 2 | 1 | 2 |
| Diluted EPS | 1.59 | 1.44 | 1.67 | 2.11 | 1.20 | 2.06 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 504.70M | 692.77M | 1.51B | 557.10M | 480.30M | 418.09M | 416.19M | 652.44M |
| Cash & ST investments | 212.88M | 500.52M | 476.38M | 346.97M | 272.19M | 219.31M | 199.60M | 406.32M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 2.24B | 2.23B | 3.08B | 3.03B | 2.81B | 2.74B | 2.75B | 3.01B |
| Total current liabilities | 311.63M | 345.98M | 408.81M | 423.65M | 431.20M | 487.66M | 507.93M | 596.82M |
| Short-term debt | 3.00M | 54.64M | 56.99M | 50.78M | 37.67M | 31.43M | 35.16M | 39.90M |
| Long-term debt | 398.09M | 286.12M | 1.07B | 838.91M | 695.08M | 648.71M | 552.67M | 657.75M |
| Total liabilities | 841,623,000.00 | 915,414,000.00 | 1,781,983,000.00 | 1,538,854,000.00 | 1,353,205,000.00 | 1,372,282,000.00 | 1,318,727,000.00 | 1,566,523,000.00 |
| Total equity | 1.40B | 1.31B | 1.30B | 1.49B | 1.46B | 1.37B | 1.43B | 1.45B |
| Retained earnings | 2.01B | 1.93B | 2.01B | 2.31B | 2.40B | 2.54B | 2.78B | 3.03B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 450.34M | 416.19M | 567.22M | 302.98M | 403.76M | 652.44M |
| Cash & ST investments | 219.02M | 199.60M | 264.69M | 56.28M | 146.98M | 406.32M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 2.79B | 2.75B | 2.87B | 2.61B | 2.74B | 3.01B |
| Total current liabilities | 540.57M | 507.93M | 576.62M | 442.89M | 580.45M | 596.82M |
| Short-term debt | 34.88M | 35.16M | 34.39M | 33.92M | 39.06M | 39.90M |
| Long-term debt | 552.19M | 552.67M | 553.15M | 504.28M | 495.64M | 657.75M |
| Total liabilities | 1,357,046,000.00 | 1,318,727,000.00 | 1,409,839,000.00 | 1,235,917,000.00 | 1,373,322,000.00 | 1,566,523,000.00 |
| Total equity | 1.43B | 1.43B | 1.46B | 1.38B | 1.36B | 1.45B |
| Retained earnings | 2.72B | 2.78B | 2.84B | 2.92B | 2.96B | 3.03B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 204.86M | 107.69M | 192.20M | 10.60M | 191.91M | 295.78M | 337.90M | 470.42M |
| Depreciation & amortization | 40.71M | 85.06M | 84.54M | 186.60M | 151.09M | 107.96M | 84.47M | 83.02M |
| Free cash flow | 147.28M | 68.09M | 152.32M | -20.45M | 165.90M | 246.88M | 287.57M | 392.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -252.85M | -136.89M | -100.00M | -120.00M | -123.13M | -261.97M | -213.13M | -239.87M |
| Ending cash balance | 205.22M | 483.38M | 1.30B | 347.94M | 275.08M | 221.20M | 201.16M | 407.75M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 207.91M | 59.69M | 130.55M | 29.74M | 186.17M | 123.96M |
| Depreciation & amortization | 24.32M | 20.45M | 20.32M | 20.95M | 20.78M | 20.97M |
| Free cash flow | 197.67M | 40.70M | 114.53M | 15.12M | 165.93M | 97.15M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -72.37M | -66.69M | -7.60M | -164.77M | -67.50M | 0 |
| Ending cash balance | 221.18M | 201.16M | 266.19M | 58.64M | 148.84M | 407.75M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 6.54 | -6.32 | 5.89 | 22.64 | 6.30 | 9.68 | 16.92 | 17.47 |
| ROA %i | 4.15 | -3.82 | 2.91 | 10.45 | 3.20 | 4.93 | 8.63 | 8.73 |
| ROIC %i | 5.97 | -4.08 | 4.83 | 14.86 | 6.12 | 7.98 | 11.99 | 12.18 |
| 5-year avg ROE %i | 4.99 | 1.93 | 3.05 | 6.00 | 6.84 | 7.47 | 12.11 | 14.53 |
| EBIT margin %i | 15.63 | 24.40 | 15.12 | 4.23 | 12.08 | 13.77 | 19.17 | 19.67 |
| FCF / sales %i | 11.30 | 6.04 | 12.90 | -- | 11.43 | 15.58 | 16.08 | 20.10 |
| Current ratioi | 1.62 | 2.00 | 3.71 | 1.32 | 1.11 | 0.86 | 0.82 | 1.09 |
| Quick ratioi | 0.95 | 1.70 | 1.27 | 1.01 | 0.87 | 0.71 | 0.68 | 0.96 |
| Debt / assetsi | 17.88 | 23.19 | 41.87 | 35.20 | 31.89 | 30.93 | 28.12 | 30.06 |
| LT debt / equityi | 28.61 | 35.27 | 94.90 | 68.12 | 58.91 | 59.63 | 51.54 | 59.85 |
| Interest coveragei | 8.20 | 13.16 | 4.07 | 0.57 | 2.77 | 4.02 | 7.73 | 9.81 |
| Revenue CAGR (3Y) %i | -2.09 | -10.48 | -2.17 | 10.87 | 18.75 | 20.79 | 8.97 | 10.44 |
| Net income CAGR (3Y) %i | -- | -- | 27.52 | 48.39 | -- | 25.00 | -8.65 | 39.16 |
| FCF CAGR (3Y) %i | -6.47 | -28.77 | -7.52 | -- | 34.56 | 17.47 | -- | 33.27 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 16.87 | 16.92 | 17.75 | 17.98 | 16.74 | 17.47 |
| ROA %i | 8.44 | 8.63 | 8.89 | 9.49 | 8.47 | 8.73 |
| ROIC %i | 12.35 | 11.99 | 12.49 | 12.61 | 12.08 | 12.18 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 19.12 | 19.17 | 19.56 | 19.38 | 19.14 | 19.67 |
| FCF / sales %i | 16.69 | 16.08 | 17.63 | 19.48 | 17.61 | 20.10 |
| Current ratioi | 0.83 | 0.82 | 0.98 | 0.68 | 0.70 | 1.09 |
| Quick ratioi | 0.71 | 0.68 | 0.80 | 0.49 | 0.56 | 0.96 |
| Debt / assetsi | 27.98 | 28.12 | 27.06 | 27.90 | 26.90 | 30.06 |
| LT debt / equityi | 52.04 | 51.54 | 50.87 | 50.45 | 51.11 | 59.85 |
| Interest coveragei | 7.03 | 7.73 | 8.64 | 9.29 | 9.10 | 9.81 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Walden is the largest reported line at 41.19% of revenue, across 3 reported segments.
- No single line clears half of revenue; Chamberlain is next at 38.39%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Walden41.19%
Chamberlain38.39%
Medical and Veterinary20.42%
Region
Domestic Operations79.58%
Barbados, St. Kitts and St. Maarten20.42%
Quote time 2026-10-08 08:19:04 · For reference only, not investment advice and not tailored to your situation.